MedTrace Logo

Efficacy of Metformin in Lean Women With Polycystic Ovary Syndrome

NCT00319293 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2006-10-11

No results posted yet for this study

Summary

Insulin resistance is an important feature of the polycystic ovary syndrome,and patiens are successfully treated with the insulin sensitizing agent metformin. The insulin resistance of lean patients with the syndrome is debated. In this study, we will study the change in insulin resistance, metabolic and hormonal factors after 3 months of metformin treatment in lean PCOS women.

Conditions

  • Polycystic Ovary Syndrome

Interventions

DRUG

Metformin

Sponsors & Collaborators

  • Aarhus University Hospital

    collaborator OTHER

  • Aarhus University Hospital Skejby

    lead OTHER

Principal Investigators

  • Birgitta Trolle, MD · Skejby University Hospital

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
35 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00319293 on ClinicalTrials.gov